Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA
Launched by METHODIST HEALTH SYSTEM · Oct 17, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA," is studying how to better treat patients with osteomyelitis, which is an infection in the bones often caused by wounds or surgery. The trial aims to find out if using certain antibiotics that target a specific bacteria called MRSA (methicillin-resistant Staphylococcus aureus) is necessary when a patient does not have a confirmed MRSA infection. The researchers want to ensure that patients receive the most appropriate treatment without unnecessary use of these antibiotics.
To participate in this trial, individuals need to be at least 18 years old and have been admitted to a military hospital for osteomyelitis in the lower limb between April 2017 and April 2023. They should also have clear imaging results showing the infection and be planned for at least four weeks of treatment with intravenous antibiotics. Participants can expect close monitoring during their treatment, helping doctors understand the best way to manage this condition. This study is currently looking for volunteers, and your involvement could contribute valuable information to improve future care for osteomyelitis patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Admission to any MHS hospital between April 1, 2017 and April 1, 2023
- • \> 18 years of age
- • Documented osteomyelitis location of the lower limb via ICD-10 code
- • Documented imaging of lower limb osteomyelitis during index admission
- • Planned intravenous (IV) antibiotics for at least 4 weeks
- Exclusion Criteria:
- • • IV antibiotics for less than 24 hours inpatient
- • Planned surgical intervention documented at admission
- • Patients receiving monotherapy with an anti-MRSA agent
- • Positive MRSA culture during index admission
- • Current outpatient antibiotic use on index admission
- • Repeated hospital admission during study period
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Matthew Crotty, PharmD
Principal Investigator
The Methodist Hospital Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported